Drug Approval | November 07, 2022
Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The laboratory is equipped to perform high-volume diagnostic testing services
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
Subscribe To Our Newsletter & Stay Updated
